NIH TCF TASK B-1

NIH TCF 任务 B-1

• 批准号: 10259989
• 负责人: JOHN ALTMAN
• 金额: $ 33.38万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2022-03-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10259989
• 关键词: Antigen Targeting; B-Lymphocytes; CD8-Positive T-Lymphocytes; Communities; Core Facility; Detection; Development; Evaluation; MHC Class I Genes; Population; Process; Production; Proteins; Reagent; T-Lymphocyte; T-Lymphocyte Epitopes; Technology; United States National Institutes of Health; adaptive immune response; improved; research and development; tool

The NIH Tetramer Core Facility (TCF) distributes high quality reagents for detection of innate T cell and classical CD4 and CD8 T cell populations. This Facility also conducts R&D to produce new reagents and improve existing tetramer technologies. The TCF is producing MHC class I and class II tetramers for isolation and characterization of specific CD4 and CD8 T cells, and is also developing Spike protein tetramers for detection and characterization of specific B cells. Thus far, 56 MHC tetramers have been distributed to the community, an additional 35 are in-process. Additional reagents will be produced and distributed as new T cell epitopes and B cell antigen targets are identified. These tetramer reagents will be invaluable tools for evaluation of adaptive immune responses.

NIH四聚体核心设施（TCF）分布了高质量的试剂，以检测先天T细胞以及经典CD4和CD8 T细胞种群。 该设施还进行研发以生产新的试剂并改善现有的四聚体技术。 TCF正在生产MHC I类和II类四聚体，用于分离和表征特定的CD4和CD8 T细胞，并且还开发了峰值蛋白四聚体以检测和表征特定的B细胞。到目前为止，已经将56个MHC四聚体分发给了社区，另外35个是进程。 作为新的T细胞表位和B细胞抗原靶标，将产生和分布其他试剂。 这些四聚体试剂将是评估适应性免疫反应的宝贵工具。